logo
Plus   Neg
Share
Email

Perrigo Settles Patent Litigation For Generic Version Of Finacea Foam, 15%

Perrigo Co. plc (PRGO) said Tuesday that it has settled its Hatch-Waxman litigation relating to its tentatively-approved generic version of Finacea Foam (azelaic acid) 15% pursued by LEO Pharma A/S, LEO Pharma Inc., and Foamix Pharmaceuticals Ltd. The company noted that terms of the settlement are confidential.

As measured by IQVIA, annual market sales for the 12 months ending February 2019 were about $61 million.

"This settlement is another example of our long-term commitment and investments in our extended topicals strategy. Our R&D, operations and legal teams continue to work diligently and relentlessly to advance our pipeline of specialized generic products that provide high quality alternatives, and savings to patients and payors," said Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Airbnb has introduced few new rules to control parties and nuisances amidst the backlash the service received after the Halloween shooting at an Airbnb rental in a San Francisco. San Francisco-based Airbnb said it is banning "open invite" parties at all of its accommodations. The company is also banning... The U.S. Food and Drug Administration has approved three generic versions of Novartis' Gilenya capsule for treating relapsing forms of multiple sclerosis. "Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA," said Janet Woodcock, director... Shares of Upscale furniture chain RH (RH) are on a tear, on the heels of an upbeat annual forecast. Today, the stock set a new all-time high of $239.88.The stock is up more than 20% from its Dec 3 opening price of $196.66, and currently trading at $237.8, and nearly three-times its 52-week low of $84.11....
RELATED NEWS
Follow RTT
>